Anti-Xa activity by weight in critically ill patients receiving unfractionated heparin for venous thromboembolism prophylaxis

被引:2
|
作者
Aggarwal, Meera, V [1 ]
Jarrell, Andrew S. [1 ]
Gilmore, Vi T. [1 ]
Aboagye, Jonathan K. [2 ]
Haut, Elliott R. [2 ,3 ,4 ,5 ,10 ]
Hobson, Deborah B. [2 ,3 ]
Lau, Brandyn D. [3 ,4 ,6 ,7 ]
Kickler, Thomas [8 ]
Kraus, Peggy S. [1 ]
Shaffer, Dauryne L. [2 ]
Shermock, Kenneth M. [1 ]
Streiff, Michael B. [3 ,9 ]
Zheng, Gang [8 ]
Kruer, Rachel M. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Pharm, 600 N Wolfe St Carnegie 180, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21218 USA
[3] Armstrong Inst Patient Safety & Qual, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Anesthesiol & Crit Care Med, Baltimore, MD 21218 USA
[6] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA
[7] Johns Hopkins Univ, Sch Med, Div Hlth Sci Informat, Baltimore, MD 21218 USA
[8] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21218 USA
[9] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21218 USA
[10] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21218 USA
关键词
Heparin; Venous thromboembolism; Deep venous thrombosis; Prophylaxis; Anti-Xa; Obese; DOSE SUBCUTANEOUS HEPARIN; DEEP-VEIN THROMBOSIS; BARIATRIC SURGERY; PREVENTION; OBESE; ENOXAPARIN; EFFICACY; THROMBOPROPHYLAXIS; STRATEGIES; OVERWEIGHT;
D O I
10.1016/j.jcrc.2019.04.027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose: This study compared a nti-Xa activity in critically ill patients receiving UFH for VTE prophylaxis between two weight groups (<100 kg vs >= 100 kg). Methods: This prospective, observational study included critically ill patients on UFH 5000 or 7500 units every 8 h. A peak and trough anti-Xa activity assay was ordered for each patient at steady state. Goal peak anti-Xa activity was 0.1-0.3 units/mL. Results: From March 2017 to June 2018, 75 patients were enrolled with 44 in the <100 kg group and 31 in the >= 100 kg group. There was no significant difference in the percentage of patients with peak anti-Xa activity within goal range between patients <100 kg and >= 100 kg (55.3% vs 35.7%, p = 0.12). The odds ratio for achieving peak anti-Xa activity within goal range as weight-based dose increased was 1.03 (95% CI 0.99-1.07). No differences were found in trough anti-Xa activity, VTE, bleeding, length of stay, or death. Conclusions: Though only one-third of patients >= 100 kg had peak anti-Xa activity within goal range, no significant difference was found between the weight groups. Additional prospective studies with adequate sample sizes are warranted to further investigate appropriate weight-based dosing of UFH in critically ill patients. (C) 2019 Elsevier Inc. All tights reserved.
引用
收藏
页码:180 / 185
页数:6
相关论文
共 50 条
  • [41] Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically Ill patients
    Young R. Lee
    Delilah D. Blanco
    Journal of Thrombosis and Thrombolysis, 2017, 44 : 386 - 391
  • [42] Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer
    Van Matre, E. T.
    Reynolds, P. M.
    MacLaren, R.
    Mueller, S. W.
    Wright, G. C.
    Moss, M.
    Burnham, E. L.
    Ho, P. M.
    Vandivier, R. W.
    Kiser, T. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (12) : 2492 - 2500
  • [43] Cost-effectiveness of Dalteparin vs Unfractionated Heparin for the Prevention of Venous Thromboembolism in Critically Ill Patients
    Fowler, Robert A.
    Mittmann, Nicole
    Geerts, William
    Heels-Ansdell, Diane
    Gould, Michael K.
    Guyatt, Gordon
    Krahn, Murray
    Finfer, Simon
    Pinto, Ruxandra
    Chan, Brian
    Ormanidhi, Orges
    Arabi, Yaseen
    Qushmaq, Ismael
    Rocha, Marcelo G.
    Dodek, Peter
    McIntyre, Lauralyn
    Hall, Richard
    Ferguson, Niall D.
    Mehta, Sangeeta
    Marshall, John C.
    Doig, Christopher James
    Muscedere, John
    Jacka, Michael J.
    Klinger, James R.
    Vlahakis, Nicholas
    Orford, Neil
    Seppelt, Ian
    Skrobik, Yoanna K.
    Sud, Sachin
    Cade, John F.
    Cooper, Jamie
    Cook, Deborah
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (20): : 2135 - 2145
  • [44] Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels
    Alex M. Ebied
    Tammy Li
    Samantha F. Axelrod
    Douglas J. Tam
    Yiqing Chen
    Journal of Thrombosis and Thrombolysis, 2020, 49 : 206 - 213
  • [45] Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels
    Ebied, Alex M.
    Li, Tammy
    Axelrod, Samantha F.
    Tam, Douglas J.
    Chen, Yiqing
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 49 (02) : 206 - 213
  • [46] Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis
    Amin, Alpesh N.
    Lin, Jay
    Lenhart, Greg
    Schulman, Kathy L.
    THROMBOSIS AND HAEMOSTASIS, 2009, 102 (02) : 321 - 326
  • [47] Economic Outcomes in Patients at Risk for Venous Thromboembolism Receiving Appropriate Enoxaparin or Unfractionated Heparin Prophylaxis.
    Amin, Alpesh
    Lin, Jay
    Lenhart, Greg
    Schulman, Kathy
    BLOOD, 2008, 112 (11) : 464 - 465
  • [48] Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma
    Jacobs, Benjamin N.
    Cain-Nielsen, Anne H.
    Jakubus, Jill L.
    Mikhail, Judy N.
    Fath, John J.
    Regenbogen, Scott E.
    Hemmila, Mark R.
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2017, 83 (01): : 151 - 158
  • [49] Aging and venous thromboembolism influence the pharmacodynamics of the Anti-Xa and Anti-IIa activities of a low molecular weight heparin (Nadroparin)
    Boneu, B
    Mismetti, P
    Laporte, S
    Navarro, C
    Sie, P
    DAzemar, P
    Necciari, J
    Duret, JP
    Gaud, C
    Decousus, H
    THROMBOSIS AND HAEMOSTASIS, 1997, : P1149 - P1149
  • [50] Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients
    Kovacs, MJ
    Levine, MN
    Keeney, M
    MacKinnon, KM
    Lee, AY
    THROMBOSIS AND HAEMOSTASIS, 2005, 93 (06) : 1185 - 1188